^
    Back
    Association details:
    Biomarker:PIK3CA mutation + HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor) +
    taselisib (GDC-0032) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncologist
    Title:

    Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer

    Published date:
    01/16/2019
    Excerpt:
     In early clinical trials, promising disease control benefits were demonstrated with the PI3K isoform-selective inhibitors alpelisib and taselisib in patients with PIK3CA-mutated HR+, HER2- ABC.
    DOI:
    10.1634/theoncologist.2018-0314